Colon cancer is a prevalent malignant tumor of digestive tract occurring in the colon. Colon cancer is the third leading cause of deaths in the world. Basic research on colon cancer is of great importance to patients with the disease.
Methods:
In this article, the authors observed the expression of KIAA0101 in different types of cancers in public database (GEPIA2), found a gene network associated with KIAA0101 in STRING database, and explored the correlation of these genes with KIAA0101 at the expression level and the immune cells associated with the expression of KIAA0101. Then the authors detected the affection of KIAA0101 to the proliferation and apoptosis of cancer cells and verified the consistency of KIAA0101 expression in 31 tumor patient tissues using the database.
Results:
KIAA0101 is differentially expressed in all kinds of tumor cells, and it shows high expression in colorectal cancer tissues. The authors found 10 genes related to KIAA0101, including CDC20, TOP2A, CCNB2, CCNA2, and so on, all of which show positive correlation with KIAA0101 expression. In addition, the result of this study showed that KIAA0101 expression had a positive correlation with the infiltration of Th1 and Th2 cells, with correlation coefficients of 0.371 and 0.627, respectively. KIAA0101 gene shows high expression in both HCT15 and SW480 cell lines. Inhibition of KIAA0101 expression can increase caspase 3/7 activity in both HCT15 and SW480 cell lines, inhibit the proliferation ability of the two cell lines, and inhibit Bcl-2 gene expression. KIAA0101 also has tumor-suppressing effects in mice. The expression of KIAA0101 gene also shows a significant increase in the tissues collected from 31 patients with tumor.
Conclusions:
Inhibition of KIAA0101 expression can regulate cell proliferation and apoptosis in colorectal cancer.
LuanL, LiN, ZhangK, et al.Diversin upregulates the proliferative ability of colorectal cancer by inducing cell cycle proteins. Exp Mol Pathol, 2023; 129:104850.
2.
ArnoldM, SierraMS, LaversanneM, et al.Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017; 66(4):683–691.
3.
TorreLA, BrayF, SiegelRL, et al.Global cancer statistics, 2012. CA Cancer J Clin, 2015; 65(2):87–108.
4.
HullR, FranciesFZ, OyomnoM, et al.Colorectal cancer genetics, incidence and risk factors: in search for targeted therapies. Cancer Manag Res, 2020; 12:9869–9882.
5.
ZhouJ, ZhengR, ZhangS, et al.Colorectal cancer burden and trends: Comparison between China and major burden countries in the world. Chin J Cancer Res, 2021; 33(1):1–10.
6.
YuP, HuangB, ShenM, et al.p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene, 2001; 20(4):484–489.
7.
NottermanDA, AlonU, SierkAJ, et al.Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res, 2001; 61(7):3124–3130.
8.
FleischmannC, BevanS, NeilJC, et al.Mutations in the candidate tumour suppressor gene FLJ12973 on chromosome 15q15 are rare in colorectal cancer. Cancer Lett, 2003; 196(1):65–67.
9.
LiY, ChenZ. Molecular cloning and characterization of LCRG1 a novel gene localized to the tumor suppressor locus D17S800-D17S930. Cancer Lett, 2004; 209(1):75–85.
10.
KargE, SmetsM, RyanJ, et al.Ubiquitome analysis reveals PCNA-Associated Factor 15 (PAF15) as a specific ubiquitination target of UHRF1 in embryonic stem cells. J Mol Biol, 2017; 429(24):3814–3824.
11.
PauneskuT, MittalS, ProticM, et al.Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol, 2001; 77(10):1007–1021.
12.
SimpsonF, Lammerts VAN BuerenK, ButterfieldN, et al.The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Exp Cell Res, 2006; 312(1):73–85.
13.
ChangCN, FengMJ, ChenYL, et al.p15(PAF) is an Rb/E2F-regulated S-phase protein essential for DNA synthesis and cell cycle progression. PLoS One, 2013; 8(4):e61196.
14.
PovlsenLK, BeliP, WagnerSA, et al.Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol, 2012; 14(10):1089–1098.
15.
EmanueleMJ, CicciaA, EliaAE, et al.Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proc Natl Acad Sci U S A, 2011; 108(24):9845–9850.
16.
TurchiL, FarehM, AberdamE, et al.ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death Differ, 2009; 16(5):728–737.
17.
LeiH, WangK, JiangT, et al.KIAA0101 and UbcH10 interact to regulate non-small cell lung cancer cell proliferation by disrupting the function of the spindle assembly checkpoint. BMC Cancer, 2020; 20(1):957.
18.
ChenY, JinY, YingH, et al.Synergistic effect of PAF inhibition and X-ray irradiation in non-small cell lung cancer cells. Strahlenther Onkol, 2021; 197(4):343–352.
19.
JainM, ZhangL, PattersonEE, et al.KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS One, 2011; 6(11):e26866.
20.
LvW, SuB, LiY, et al.KIAA0101 inhibition suppresses cell proliferation and cell cycle progression by promoting the interaction between p53 and Sp1 in breast cancer. Biochem Biophys Res Commun, 2018; 503(2):600–606.
21.
JinC, LiuZ, LiY, et al.PCNA-associated factor P15(PAF), targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients. Int J Cancer, 2018; 143(11):2973–2984.
22.
LiuL, ChenX, XieS, et al.Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology, 2012; 56(5):1760–1769.
23.
JainN, RoyJ, DASB, et al.miR-197-5p inhibits sarcomagenesis and induces cellular senescence via repression of KIAA0101. Mol Carcinog, 2019; 58(8):1376–1388.
24.
ZhuY, ZhouC, HeQ. High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: A pooled analysis. J Int Med Res, 2019; 47(1):383–390.
25.
SamantarraiD, MallickB. miR-429 inhibits metastasis by targeting KIAA0101 in soft tissue sarcoma. Exp Cell Res, 2017; 357(1):33–39.
26.
HosokawaM, TakeharaA, MatsudaK, et al.Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res, 2007; 67(6):2568–2576.
27.
RoigAI, EskiocakU, HightSK, et al.Immortalized epithelial cells derived from human colon biopsies express stem cell markers and differentiate in vitro. Gastroenterology, 2010; 138(3):1012–1021. e1-5.
28.
VermeulenK, VAN BockstaeleDR, BernemanZN. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif, 2003; 36(3):131–149.
29.
PetriET, ErricoA, EscobedoL, et al.The crystal structure of human cyclin B. Cell Cycle, 2007; 6(11):1342–1349.
30.
WuT, ZhangX, HuangX, et al.Regulation of cyclin B2 expression and cell cycle G2/m transition by menin. J Biol Chem, 2010; 285(24):18291–18300.
31.
ShubbarE, KovacsA, HajizadehS, et al.Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcome. BMC Cancer, 2013; 13:1.
32.
ToolabiN, DaliriFS, MokhlesiA, et al.Identification of key regulators associated with colon cancer prognosis and pathogenesis. J Cell Commun Signal, 2022; 16(1):115–127.
33.
GanW, ZhaoH, LiT, et al.CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway. Oncotarget, 2017; 8(42):71618–71629.
34.
TongY, HuangY, ZhangY, et al.Correction: DPP3/CDK1 contributes to the progression of colorectal cancer through regulating cell proliferation, cell apoptosis, and cell migration. Cell Death Dis, 2021; 12(7):623.
35.
DaiS, MoY, WangY, et al.Chronic stress promotes cancer development. Front Oncol, 2020; 10:1492.
36.
GanY, LiY, LiT, et al.CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res, 2018; 10:5113–5124.
37.
LiJ, ZhouL, LiuY, et al.Comprehensive analysis of cyclin family gene expression in colon cancer. Front Oncol, 2021; 11:674394.
38.
DingX, DuanH, LuoH. Identification of core gene expression signature and key pathways in colorectal cancer. Front Genet, 2020; 11:45.
39.
WuKZ, WangGN, FitzgeraldJ, et al.DDK dependent regulation of TOP2A at centromeres revealed by a chemical genetics approach. Nucleic Acids Res, 2016; 44(18):8786–8798.
40.
TerashimaM, IchikawaW, OchiaiA, et al.; ACTS-GC Group. TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study. Oncotarget, 2017; 8(34):57574–57582.
41.
ZhangHP, LiSY, WangJP, et al.Clinical significance and biological roles of cyclins in gastric cancer. Onco Targets Ther, 2018; 11:6673–6685.
42.
ZhangR, XuJ, ZhaoJ, et al.Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A. J Cell Biochem, 2018; 119(9):7256–7263.
43.
YuH. Cdc20: A WD40 activator for a cell cycle degradation machine. Mol Cell, 2007; 27(1):3–16.
44.
Thornton BR, ToczyskiDP. Precise destruction: An emerging picture of the APC. Genes Dev, 2006; 20(22):3069–3078.
45.
PinesJ. Mitosis: A matter of getting rid of the right protein at the right time. Trends Cell Biol, 2006; 16(1):55–63.
46.
PetersJM. The anaphase promoting complex/cyclosome: A machine designed to destroy. Nat Rev Mol Cell Biol, 2006; 7(9):644–656.
47.
HanahanD, WeinbergRA. Hallmarks of cancer: The next generation. Cell, 2011; 144(5):646–674.
48.
ShiJ, OrthJD, MitchisonT. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res, 2008; 68(9):3269–3276.
49.
SymmansWF, VolmMD, ShapiroRL, et al.Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: Implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res, 2000; 6(12):4610–4617.
50.
GascoigneKE, TaylorSS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell, 2008; 14(2):111–122.
51.
HuangHC, ShiJ, OrthJD, et al.Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell, 2009; 16(4):347–358.
52.
KidokoroT, TanikawaC, FurukawaY, et al.CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene, 2008; 27(11):1562–1571.
